The underlying liver disease conditions at cohort entry
| Phenotype | Full cohort, n=111 098* | Primary care group, n=20 319* | Secondary care group, n=56 710* | Mortality group, n=3459* | Multi-source group, n=30 610* |
| Chronic liver disease | |||||
| Stage 1—tier 1 | 79 992 (72.0%) | 18 453 (90.8%) | 35 102 (61.9%) | 1728 (50.0%) | 24 709 (80.7%) |
| ArLD | 19 760 (17.8%) | 2116 (10.4%) | 4566 (8.1%) | 887 (25.6%) | 12 191 (39.8%) |
| NAFLD | 33 655 (30.3%) | 13 565 (66.8%) | 13 444 (23.7%) | 727 (21.0%) | 5919 (19.3%) |
| Metabolic liver disease | 5469 (4.9%) | 782 (3.8%) | 3887 (6.9%) | 69 (2.0%) | 731 (2.4%) |
| HBV | 1063 (1.0%) | 0 (0.0%) | 905 (1.6%) | 0 (0.0%) | 158 (0.5%) |
| HCV | 3539 (3.2%) | 0 (0.0%) | 2697 (4.8%) | 13 (0.4%) | 829 (2.7%) |
| Autoimmune liver disease | 13 582 (12.2%) | 815 (4.0%) | 9060 (16.0%) | 199 (5.8%) | 3508 (11.5%) |
| Haemochromatosis | 4111 (3.7%) | 1209 (6.0%) | <940 (<1.7%) | <10(<0.2%) | 1958 (6.4%) |
| ArLD overlap | 799 (0.7%) | 15 (0.1%) | 158 (0.3%) | 173 (5.0%) | 453 (1.5%) |
| Non-ArLD overlap | 371 (0.3%) | <20 (<0.1%) | 228 (0.4%) | <10 (<0.2%) | 123 (0.4%) |
| Stage 1—tier 2 | 6111 (5.5%) | 81 (0.4%) | 4906 (8.7%) | 127 (3.7%) | 997 (3.3%) |
| Hepatitis not specified | 4783 (4.3%) | 11 (0.1%) | 3867 (6.8%) | 102 (2.9%) | 803 (2.6%) |
| Congestive hepatopathy | 574 (0.5%) | <10 (<0.1%) | 514 (0.9%) | <10 (<0.2%) | <60 (<0.2%) |
| Toxic liver disease | 757 (0.7%) | 68 (0.3%) | 526 (0.9%) | 21 (0.6%) | 142 (0.5%) |
| Stage 1—tier 3 | 8426 (7.6%) | 36 (0.2%) | 8132 (14.3%) | 37 (1.1%) | 221 (0.7%) |
| Miscellaneous | 8426 (7.6%) | 36 (0.2%) | 8132 (14.3%) | 37 (1.1%) | 221 (0.7%) |
| Stage 2 | 4562 (4.1%) | 506 (2.5%) | 1664 (2.9%) | 690 (19.9%) | 1702 (5.6%) |
| Hepatic fibrosis | 261 (0.2%) | 64 (0.3%) | 135 (0.2%) | <10 (<0.2%) | <60 (<0.2%) |
| Cirrhosis | 4301 (3.9%) | 442 (2.2%) | 1529 (2.7%) | 682 (19.7%) | 1648 (5.4%) |
| Stage 3 | 3040 (2.7%) | 166 (0.8%) | 2171 (3.8%) | 43 (1.2%) | 660 (2.2%) |
| Portal hypertension | 3040 (2.7%) | 166 (0.8%) | 2171 (3.8%) | 43 (1.2%) | 660 (2.2%) |
| Stage 4 | 3221 (2.9%) | 53 (0.3%) | 2517 (4.4%) | 276 (8.0%) | 375 (1.2%) |
| Hepatic decompensation | 3221 (2.9%) | 53 (0.3%) | 2517 (4.4%) | 276 (8.0%) | 375 (1.2%) |
| Stage 5 | 2233 (2.0%) | 121 (0.6%) | 341 (0.6%) | 473 (13.7%) | 1298 (4.2%) |
| Hepatocellular carcinoma | 748 (0.7%) | 71 (0.3%) | 83 (0.1%) | 86 (2.5%) | 508 (1.7%) |
| Intrahepatic cholangiocarcinoma | 1455 (1.3%) | 47 (0.2%) | 232 (0.4%) | 387 (11.2%) | 789 (2.6%) |
| Other primary liver cancer | 39 (0.0%) | <10 (<0.1%) | 26 (0.0%) | <10 (<0.2%) | <10 (<0.1%) |
| Acute liver disease | |||||
| Acute liver disease | 3513 (3.2%) | 903 (4.4%) | 1877 (3.3%) | 85 (2.5%) | 648 (2.1%) |
| Budd-Chiari | 184 (0.2%) | <10 (<0.1%) | 144 (0.3%) | <20 (<0.1%) | 20 (0.1%) |
| Acute liver failure | 27 (0.0%) | <30 (<0.2%) | 0 (0.0%) | 0 (0.0%) | <10 (<0.1%) |
| Infection/infarction | 1343 (1.2%) | 62 (0.3%) | 757 (1.3%) | 67 (1.9%) | 457 (1.5%) |
| Other non-specified acute liver injuries | 71 (0.1%) | 45 (0.2%) | <20 (<0.1%) | 0 (0.0%) | <10 (<0.1%) |
*n (%).
ArLD, alcohol-related liver disease; HBV, hepatitis B virus; HCV, hepatitis C virus; NAFLD, non-alcohol fatty liver disease.